Literature DB >> 23470626

Lipoxin A(4) activates alveolar epithelial sodium channel, Na,K-ATPase, and increases alveolar fluid clearance.

Qian Wang1, Qing-Quan Lian, Ru Li, Bin-Yu Ying, Qian He, Fang Chen, Xia Zheng, Yi Yang, De-Rong Wu, Sheng-Xing Zheng, Chang-Jiang Huang, Fang Gao Smith, Sheng-Wei Jin.   

Abstract

Edema fluid resorption is critical for gas exchange, and both alveolar epithelial sodium channel (ENaC) and Na,K-ATPase are accredited with key roles in the resolution of pulmonary edema. Alveolar fluid clearance (AFC) was measured in in situ ventilated lungs by instilling isosmolar 5% BSA solution with Evans Blue-labeled albumin tracer (5 ml/kg) and measuring the change in Evans Blue-labeled albumin concentration over time. Treatment with lipoxin A4 and lipoxin receptor agonist (5(S), 6(R)-7-trihydroxymethyl 17 heptanoate) significantly stimulated AFC in oleic acid (OA)-induced lung injury, with the outcome of decreased pulmonary edema. Lipoxin A4 and 5(S), 6(R)-7-trihydroxymethyl 17 heptanoate not only up-regulated the ENaC α and ENaC γ subunits protein expression, but also increased Na,K-ATPase α1 subunit protein expression and Na,K-ATPase activity in lung tissues. There was no significant difference of intracellular cAMP level between the lipoxin A4 treatment and OA group. However, the intracellular cGMP level was significantly decreased after lipoxin A4 treatment. The beneficial effects of lipoxin A4 were abrogated by butoxycarbonyl-Phe-Leu-Phe-Leu-Ph (lipoxin A4 receptor antagonist) in OA-induced lung injury. In primary rat alveolar type II epithelial cells stimulated with LPS, lipoxin A4 increased ENaC α and ENaC γ subunits protein expression and Na,K-ATPase activity. Lipoxin A4 stimulated AFC through activation of alveolar epithelial ENaC and Na,K-ATPase.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23470626     DOI: 10.1165/rcmb.2012-0274OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  27 in total

Review 1.  Specialized Proresolving Mediators in Innate and Adaptive Immune Responses in Airway Diseases.

Authors:  Nandini Krishnamoorthy; Raja-Elie E Abdulnour; Katherine H Walker; Braden D Engstrom; Bruce D Levy
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

2.  Resolvin D3 and Aspirin-Triggered Resolvin D3 Are Protective for Injured Epithelia.

Authors:  Jennifer K Colby; Raja-Elie E Abdulnour; Ho Pan Sham; Jesmond Dalli; Romain A Colas; Jeremy W Winkler; Jason Hellmann; Blenda Wong; Ye Cui; Souheil El-Chemaly; Nicos A Petasis; Matthew Spite; Charles N Serhan; Bruce D Levy
Journal:  Am J Pathol       Date:  2016-05-10       Impact factor: 4.307

3.  Mechanism of action of novel lung edema therapeutic AP301 by activation of the epithelial sodium channel.

Authors:  Waheed Shabbir; Parastoo Scherbaum-Hazemi; Susan Tzotzos; Bernhard Fischer; Hendrik Fischer; Helmut Pietschmann; Rudolf Lucas; Rosa Lemmens-Gruber
Journal:  Mol Pharmacol       Date:  2013-09-27       Impact factor: 4.436

4.  Resolvin D1 Improves the Resolution of Inflammation via Activating NF-κB p50/p50-Mediated Cyclooxygenase-2 Expression in Acute Respiratory Distress Syndrome.

Authors:  Ye Gao; Huawei Zhang; Lingchun Luo; Jing Lin; Dan Li; Sisi Zheng; Hua Huang; Songfan Yan; Jingxiang Yang; Yu Hao; Hui Li; Fang Gao Smith; Shengwei Jin
Journal:  J Immunol       Date:  2017-08-09       Impact factor: 5.422

5.  The Effect and Mechanism of Lipoxin A4 on Neutrophil Function in LPS-Induced Lung Injury.

Authors:  Wen-Hao Pan; Xin Hu; Ben Chen; Qi-Chao Xu; Hong-Xia Mei
Journal:  Inflammation       Date:  2022-04-19       Impact factor: 4.657

6.  Lipoxin A4 activates alveolar epithelial sodium channel gamma via the microRNA-21/PTEN/AKT pathway in lipopolysaccharide-induced inflammatory lung injury.

Authors:  Wei Qi; Hui Li; Xiao-Hong Cai; Jia-Qi Gu; Jin Meng; Hai-Qing Xie; Jun-Li Zhang; Jie Chen; Xian-Guan Jin; Qian Tang; Yu Hao; Ye Gao; Ai-Qing Wen; Xiang-Yang Xue; Fang Gao Smith; Sheng-Wei Jin
Journal:  Lab Invest       Date:  2015-08-24       Impact factor: 5.662

7.  BML-11, a lipoxin receptor agonist, protected carbon tetrachloride-induced hepatic fibrosis in rats.

Authors:  Xiao-Yan Zhou; Zhong-Jian Yu; Dan Yan; Hong-Mei Wang; Yong-Hong Huang; Juan Sha; Fang-Yun Xu; Zhen-Yu Cai; Wei-Ping Min
Journal:  Inflammation       Date:  2013-10       Impact factor: 4.092

8.  Lipoxin A4 ameliorates alveolar fluid clearance disturbance in lipopolysaccharide-induced lung injury via aquaporin 5 and MAPK signaling pathway.

Authors:  Fang Ba; Xiaoming Zhou; Yingqi Zhang; Cen Wu; Shenqian Xu; Liqin Wu; Jiayang Li; Yan Yin; Xiu Gu
Journal:  J Thorac Dis       Date:  2019-08       Impact factor: 2.895

Review 9.  Review of the potential of mesenchymal stem cells for the treatment of infectious diseases.

Authors:  Amit Sharma; Anuja Chakraborty; Bithiah Grace Jaganathan
Journal:  World J Stem Cells       Date:  2021-06-26       Impact factor: 5.326

10.  Physiological levels of lipoxin A4 inhibit ENaC and restore airway surface liquid height in cystic fibrosis bronchial epithelium.

Authors:  Mazen Al-Alawi; Paul Buchanan; Valia Verriere; Gerard Higgins; Olive McCabe; Richard W Costello; Paul McNally; Valérie Urbach; Brian J Harvey
Journal:  Physiol Rep       Date:  2014-08-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.